Evidence map›Paper›PMID 42707222›Full record

ReviewJournal of bone oncology2026

Bone metastases from hepatocellular carcinoma: Guidance on the management of spinal and long bone lesions.

Shanmei Lyu, Difan Zhou

Abstract readReview
In one paragraph

Review in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shanmei LyuDepartment of Clinical Laboratory, Shaoxing People's Hospital, Shaoxing, Zhejiang, PR China.
Difan ZhouDepartment of Hepatobiliary and Pancreatic Surgery, Shaoxing People's Hospital, Shaoxing, Zhejiang, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone metastasis from hepatocellular carcinoma (HCC) is a marker of advanced disease and a potential cause of preventable functional loss. HCC skeletal lesions are commonly osteolytic and may be hypervascular, creating risks of pathological fracture, spinal instability, metastatic spinal cord compression (MSCC), neurological deficit, and loss of ambulation. This structured narrative review integrates HCC-specific clinical evidence with established orthopedic and spine oncology frameworks to identify when specialist consultation should occur before irreversible skeletal or neurological deterioration. Retrospective HCC cohorts indicate that the spine is frequently involved, that surveillance-detected metastases were associated with a lower observed frequency of fracture or paralysis than symptom-detected metastases, and that hepatic reserve was associated with outcomes after skeletal surgery. Because direct HCC-specific comparative evidence remains limited, the Spinal Instability Neoplastic Score (SINS), epidural spinal cord compression (ESCC)/Bilsky grading, the neurological, oncological, mechanical, and systemic (NOMS) framework, prognostic scores, Patchell's MSCC evidence, and Mirels score are used as communication aids rather than disease-specific operative thresholds. We propose a conceptual four-pathway triage model for neurological emergency, spinal mechanical failure, long-bone fracture risk, and pelvic or acetabular weight-bearing failure, followed by a systemic-fitness assessment incorporating liver reserve, hemostatic status, prognosis, rehabilitation potential, and patient goals. The framework is intended to accelerate multidisciplinary assessment, not to prescribe surgery.

Indexed as

Bone metastasisFunctional-risk triageHepatocellular carcinomaMetastatic spinal cord compressionOrthopedic oncologySpinal metastasis

Identifiers

PMID42707222
PMCPMC13546973

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.